Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 50,319 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasms Clear all
Completed Phase 1 Interventional Results available

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

NCT03708328
View directory record Official record
Conditions
Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
Lomvastomig
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 24, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional

ALLPS VERSUS PVO Randomized Controlled Trial

NCT01775267
View directory record Official record
Conditions
Liver Tumors Not Resectable in One Surgical Procedure
Interventions
Associating liver partition and portal vein ligation for staged hepatectomy, Portal vein embolization or ligation
Procedure
Lead sponsor
University of Zurich
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

NCT00005965
View directory record Official record
Conditions
Cervical Cancer
Interventions
bryostatin 1, cisplatin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
New York, New York • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 24, 2026, 1:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT03914300
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

NCT00016900
View directory record Official record
Conditions
Esophageal Cancer
Interventions
liposomal paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer

NCT00675636
View directory record Official record
Conditions
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
Interventions
study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors
Other · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

NCT06030011
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
NYU Electronic Patient Visit Assessment (ePVA), Usual Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Kansas City, Kansas • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial

NCT07282444
View directory record Official record
Conditions
Lung Carcinoma, Head and Neck Carcinoma
Interventions
Training and Education, Communication Intervention, Survey Administration, Interview, Electronic Health Record Review
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

NCT06741644
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
CS2009, Pemetrexed, Carboplatin, Paclitaxel, Etoposide, Nab-paclitaxel, Oxaliplatin, Capecitabine, Docetaxel, Leucovorin, 5-FU, Cisplatin, Gemcitabine, Irinotecan
Drug
Lead sponsor
CStone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6

NCT00900744
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

NCT07072234
View directory record Official record
Conditions
Clear Cell Carcinoma, Phase 1, Growth Factor
Interventions
Lymphodepleting chemotherapy, Dexamethasone, Fludarabine, Cyclophosphamate, TGFBR-2 KO CD70 CAR NK
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

NCT00193934
View directory record Official record
Conditions
Cancer of the Uterine Cervix
Interventions
Not listed
Lead sponsor
Trans Tasman Radiation Oncology Group
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Phase 2 Interventional

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

NCT07710534
View directory record Official record
Conditions
Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms
Interventions
Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

NCT01239134
View directory record Official record
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 24, 2026, 1:53 AM EDT
Withdrawn Phase 2 Interventional

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

NCT06943664
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium, Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy, Magnetic Resonance Imaging, Photoimmunotherapy, Positron Emission Tomography, Robotic Bronchoscopy, Video-Assisted Thoracic Surgery
Procedure · Biological · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Bright Light Therapy on Fatigue, Sleep and Circadian Activity Rhythms in Lung Cancer Survivors

NCT02954809
View directory record Official record
Conditions
Fatigue, Sleep Disturbance, Circadian Dysregulation
Interventions
Morning bright light therapy, Dim light
Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional

Clinical Evaluation of a Treatment Planning Software and Oncology Information System for Proton Therapy

NCT07759999
View directory record Official record
Conditions
Proton Therapy
Interventions
Treatment Planning Software
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00295932
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
rituximab, bortezomib, cyclophosphamide, prednisone
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
8
States / cities
Atlanta, Georgia • Basking Ridge, New Jersey • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients

NCT02932332
View directory record Official record
Conditions
Cancer
Interventions
High-flow Oxygen, Low-flow Oxygen, High-flow Air, Low-flow Air
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 24, 2026, 1:53 AM EDT
Completed No phase listed Observational

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

NCT01800032
View directory record Official record
Conditions
Neurofibromatosis-1, Optic Glioma, Plexiform Neurofibroma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00251498
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
82 participants
Timeline
Ends 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2008 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Interventions to Increase Colorectal Cancer Screening

NCT03200366
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tailored DVD, Patient Navigation
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
45 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 24, 2026, 1:53 AM EDT
Active, not recruiting Phase 3 Interventional

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651
View directory record Official record
Conditions
T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepato-splenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy Associated T-cell Lymphoma, NK T-cell Lymphoma
Interventions
Brentuximab vedotin
Drug
Lead sponsor
Deepa Jagadeesh
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Detroit, Michigan • Hackensack, New Jersey • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 24, 2026, 1:53 AM EDT